Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Menorrhagia Stories

2009-07-28 08:00:00

BEDFORD, Mass., July 28 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its NovaSure(R) system--a 90-second, outpatient treatment for women suffering from excessive menstrual bleeding--has passed the one million mark for number of procedures performed. Scott Schade, M.D., an...

2009-06-02 09:44:00

Because bleeding from the reproductive tract is a naturally occurring event during menstruation and childbirth, women who exhibit menorrhagia, or excessive bleeding after their menstrual cycle, may have underlying diseases that are underdiagnosed. In order to address important issues related to the diagnosis and management of reproductive tract bleeding in women with bleeding disorders, a consensus conference was convened. Results are published in the July 2009 issue of the American Journal...

2009-06-02 09:21:20

 Nearly one percent of the population suffers from bleeding disorders, yet many women don't know they have one because doctors aren't looking for the condition, according to researchers at Duke University Medical Center.That's about to change, now that an international expert consortium specifically outlined the definitive signs that may signal the presence of a bleeding disorder in women. The consortium's recommendations are published online and will appear in the July issue of the...

2009-05-18 13:16:00

Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced additional positive safety and efficacy results from its Phase IIb clinical trial known as the Petal Study (603 study) using its proprietary,...

2009-04-02 07:31:00

NEWPORT, Ky., April 2 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms. On January 30, 2009, Xanodyne submitted the New Drug Application (NDA) for XP12B, a unique oral therapy which acts as a...

2009-03-25 16:02:00

STUDY CONFIRMS EFFICACY IN VALIDATED ENDPOINTS; MIXED RESULTS IN EXPLORATORY ENDPOINTS COMPANY TO HOST CONFERENCE CALL AND WEBCAST THURSDAY, MARCH 26TH AT 8:00AM ET / 5:00AM PT SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from its fourth Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with...

2009-01-06 10:48:46

Experts estimate that 20 percent of women experience excessive or prolonged menstrual bleeding at some time during their lives, particularly as they approach menopause. A new, less invasive procedure called global endometrial ablation (GEA) preserves the uterus, while decreasing menstrual bleeding and shortening patients' recovery time. In an article published in the January issue of Obstetrics and Gynecology, Mayo Clinic researchers attempt to determine the percentage of women who do not...

2008-10-29 21:00:04

LAS VEGAS, Oct. 29 /PRNewswire/ -- At the annual meeting of the American Association of Gynecologic Laparoscopists (AAGL), ETHICON Women's Health & Urology today announced results of a seven-country study measuring the effects of uterine fibroids and associated symptoms on quality of life (QoL). Researchers found that one in five women suffer with symptomatic fibroids for more than 5 years before getting medical treatment. Further, despite diagnosis, more than one-third of women remain...

2008-10-23 09:00:10

Columbia Laboratories, Inc. (Nasdaq: CBRX) has signed an agreement with the Perinatology Research Branch (PRB) of the Eunice Kennedy Shriver National Institutes of Child Health and Human Development (NICHD) for collaboration in Columbia Laboratories' ongoing PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study of PROCHIEVE(R) 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy. The PRB is headed by Roberto Romero, MD. "The NICHD...

2008-09-29 09:00:15

Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced results from its Phase II study of vaginally-administered lidocaine, which the Company is investigating for the prevention and treatment of dysmenorrhea. No treatment currently exists to prevent dysmenorrhea. Seventy women with a history of moderate-to-severe dysmenorrhea participated in this first documented attempt to show prevention of uterine cramping and pain. This double-blind, placebo-controlled clinical trial used a...